Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
19.24
-0.37 (-1.89%)
Feb 21, 2025, 4:00 PM EST - Market closed
Cartesian Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Cartesian Therapeutics stock have an average target of 41.67, with a low estimate of 39 and a high estimate of 45. The average target predicts an increase of 116.58% from the current stock price of 19.24.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cartesian Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 6 | 6 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +133.89% | Jan 28, 2025 |
| Needham | Needham | Strong Buy Reiterates $41 | Strong Buy | Reiterates | $41 | +113.10% | Jan 27, 2025 |
| Needham | Needham | Strong Buy Reiterates $41 | Strong Buy | Reiterates | $41 | +113.10% | Jan 13, 2025 |
| BTIG | BTIG | Strong Buy Initiates $42 | Strong Buy | Initiates | $42 | +118.30% | Dec 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $41 → $45 | Strong Buy | Reiterates | $41 → $45 | +133.89% | Dec 4, 2024 |
Financial Forecast
Revenue This Year
40.57M
from 26.00M
Increased by 56.02%
Revenue Next Year
5.61M
from 40.57M
Decreased by -86.17%
EPS This Year
-5.08
from -49.80
EPS Next Year
-3.57
from -5.08
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 42.2M | 25.2M | 25.2M | |||
| Avg | 40.6M | 5.6M | 9.0M | |||
| Low | 38.5M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 62.2% | -37.9% | 349.2% | |||
| Avg | 56.0% | -86.2% | 60.0% | |||
| Low | 48.1% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -4.33 | -1.71 | -1.69 |
| Avg | -5.08 | -3.57 | -3.79 |
| Low | -5.44 | -4.23 | -5.13 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.